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Abstract: Inﬂ  uenza is a major respiratory pathogen, which exerts a huge human and economic 
toll on society. Inﬂ  uenza is a vaccine preventable disease, however, the vaccine strains must 
be annually updated due to the continuous antigenic changes in the virus. Inactivated inﬂ  uenza 
vaccines have been used for over 50 years and have an excellent safety record. Annual vaccina-
tion is therefore recommended for all individuals with serious medical conditions, like COPD, 
and protects the vaccinee against inﬂ  uenza illness and also against hospitalization and death. 
In COPD patients, inﬂ  uenza infection can lead to exacerbations resulting in reduced quality of 
life, hospitalization and death in the most severe cases. Although there is only limited literature 
on the use of inﬂ  uenza vaccination solely in COPD patients, there is clearly enough evidence 
to recommend annual vaccination in this group. This review will focus on inﬂ  uenza virus and 
prophylaxis with inactivated inﬂ  uenza vaccines in COPD patients and other “at risk” groups to 
reduce morbidity, save lives, and reduce health care costs.
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Introduction
Inﬂ  uenza virus is one of the leading causes of viral disease resulting in widespread 
morbidity, a large number of lives lost and substantial economic loss. During annual 
inﬂ  uenza outbreaks, an estimated 5%–15% of the world’s population is infected causing 
an estimated one million deaths every year (WHO 2002; Yewdell and Garcia-Sastre 
2002). Moreover, we are currently facing a potential new pandemic that could cause 
unprecedented levels of global morbidity and mortality, particularly in the developing 
countries but also in the industrialized world. Today’s inactivated inﬂ  uenza vaccines 
provide satisfactory protection against seasonal inﬂ  uenza in healthy adults (Beyer et al 
2002; WHO 2005) and annual vaccination is cost effective (Nichol et al 1995). How-
ever, there is still room for improvement in current vaccines, especially in the elderly 
“at risk” groups where vaccine efﬁ  cacy is not optimal. Two classes of antiviral agents 
are also licensed for therapeutic and prophylactic use against inﬂ  uenza, complementing 
but not replacing, the use of inﬂ  uenza vaccines (Reviewed in Oxford et al 2003).
In man, inﬂ  uenza virus is transmitted via droplets expelled upon coughing and 
sneezing and normally infects the epithelial cells of the upper respiratory tract 
(Nicholson 1998). The incubation period is usually 2–3 days, but can be as long as 
7 days. The patient is generally contagious during the febrile phase, but cases of viral 
spread have been observed prior to the onset of symptoms (Nicholson 1998). The 
duration of illness is usually one week and is normally accompanied by high fever, 
headache, myalgia, sore throat and rhinitis. People with low levels of viral shedding 
often have fewer clinical symptoms or are asymptomatic (Murphy et al 1973; Murphy 
and Webster 1996).International Journal of COPD 2007:2(3) 230
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Healthy people usually recover within one week of ill-
ness without requiring any medical intervention. In the very 
young, the elderly and people with underlying medical prob-
lems (eg, chronic obstructive pulmonary disease (COPD), 
diabetes, cancer, heart disease) inﬂ  uenza poses a serious 
risk, and infection may lead to hospitalization and in some 
cases death (Nguyen-Van-Tam 1998). Frequently, the cause 
of hospitalization or death is viral pneumonia or second-
ary bacterial pneumonia. Substantial levels of community 
morbidity occur during an inﬂ  uenza outbreak, resulting in a 
signiﬁ  cant strain on the health care system. The economic 
burden of inﬂ  uenza on society can also be signiﬁ  cant. In the 
USA alone, a conservative estimate predicted an annual loss 
of 12–17 billion dollars (Williams et al 1988; WHO 2005).
Respiratory tract infections such as inﬂ  uenza often lead to 
exacerbation of disease in COPD patients. Inﬂ  uenza infection 
in such patients requires increased medical intervention and 
serious complications can result in hospitalization and death 
(Yap et al 2004). Each exacerbation in COPD patients leads 
to a progressive irreversible decrease in lung function, the 
frequency and severity of the exacerbations increases as the 
disease worsens (Niewoehner 2006). The patient’s quality 
of life therefore deteriorates with an increased need for hos-
pitalization. Importantly, inﬂ  uenza is a vaccine preventable 
disease and this review will focus on inﬂ  uenza virus and 
prophylaxis with inactivated inﬂ  uenza vaccines in “at risk” 
groups, herein COPD patients.
The inﬂ  uenza virus and its life cycle
Influenza belongs to the family of Orthomyxoviridae 
(Fauquet et al 2004). There are three types of inﬂ  uenza, 
A, B and C, which are classiﬁ  ed on the basis of antigenic 
differences in the internal proteins (nucleoprotein (NP) and 
matrix (M1) protein). Inﬂ  uenza A and B viruses are impor-
tant human pathogens, whereas inﬂ  uenza C infection results 
only in a mild respiratory infection in man and will not be 
discussed further in this review. The inﬂ  uenza A genus is 
further subdivided based on the antigenic properties of its 
surface glycoproteins, the haemagglutinin (HA or H) and 
the neuraminidase (NA or N). Currently, there are 16 HA 
and 9 NA subtypes recognized by the WHO (WHO 2005) 
and of these the H3N2 and H1N1 subtypes are circulating 
widely in man today.
Inﬂ  uenza virus has a negative sense, segmented, single 
stranded (ss) RNA genome. The genome of inﬂ  uenza A virus 
has 8 segments, each coding for one or two proteins, in all a 
total of 11 proteins (Table 1). Each segment is encapsulated 
by the NP to form a ribonucleoprotein complex (RNP). 
Bound to each RNP, is the viral RNA polymerase complex, 
consisting of the three viral gene products (PB1, PB2, PA) 
(Figure 1). Three viral proteins are found in the viral enve-
lope of inﬂ  uenza A virus; the HA, NA and the ion channel 
protein M2. The M1 protein lines the viral envelope in close 
proximity to the RNP and is hypothesized to interact with 
the cytoplasmic tails of the surface glycoproteins (Lamb and 
Krug 1996). The virion is pleomorphic in structure, the main 
form is a spherical particle (80–120 nm in diameter), but also 
ﬁ  lamentous and bean-like structures are found.
The HA and NA are the major antigenic proteins of the 
virus. Most antibodies produced are directed against these 
proteins and they will be brieﬂ  y discussed here. The HA is 
a trimeric protein, composed of three identical monomers, 
which must be post-translationally cleaved by cellular prote-
ases in order to be functional (Colman 1994). The distal tip 
of HA contains the receptor binding sites and the transmem-
brane stalk attaches the HA to the viral envelope (Figure 1). 
NA is a tetramer with a mushroom shape and contains the 
viral enzyme (neuraminidase), which is responsible for re-
lease of newly assembled virus from the cell. The antiviral 
drugs Oseltamivir and Zanamivir bind to the enzymatic site 
of NA, reducing or hindering the release of new virus.
Inﬂ  uenza virus replicates in the epithelial cells lining the 
respiratory tract. The enzymatic activity of NA helps the virus 
in navigating through the mucus layer and upon cell contact 
allows the HA to attach to the sialic acid containing host 
cell receptor. The virus particle is then engulfed and taken 
up into the cell in a vesicle (endosome) in a process called 
receptor-mediated endocytosis (Lamb and Krug 1996). The 
low pH initiates a conformational change in the HA molecule 
facilitating a fusion with the endosomal membrane. At the 
same time the M2 ion channel protein lowers the pH inside 
the virion, so that the RNPs become disassociated from M1, 
allowing the RNPs to enter the cytosol. The M2 protein is 
Table 1 Inﬂ  uenza A proteins
Protein   Function 
HA  Receptor binding and release of viral genome. Most 
  important antigenic protein. Trimeric structure. 
NA  Second most important antigenic determinant. 
  Tetrameric enzymatic protein and target for antiviral 
 treatment. 
M2  Tetrameric H+ ion channel and target for antiviral 
 treatment 
PB1, PB2, PA  Viral polymerase complex 
NP   Nucleoprotein 
M1   Structural matrix protein 
NS1, NS2, PB1-F2   Regulatory proteins and RNA transport International Journal of COPD 2007:2(3) 231









the target for the inﬂ  uenza antiviral drugs Amantadine and 
Rimantadine (Oxford et al 2003).
The RNPs migrate to the nucleus and the viral polymerase 
complex transcribes and replicates the viral RNA to form new 
viral RNA and mRNA. The NP and the M1 are translated in 
the cytosol, before they migrate to the nucleus to take part 
in the RNP assembly and transport. Viral proteins, possibly 
NP, may regulate the switch between transcription and 
replication (Portela and Digard 2002). New viral genomes 
are encapsidated by NP and migrate to the cytosol. The HA, 
NA and the M2 proteins are translated on the endoplasmatic 
reticulum and transported to the cell membrane. M1 and 
RNPs interact with the cytoplasmic tails of HA and NA at 
the cell membrane. The M1 protein further interacts with cel-
lular proteins and is involved in determining both the virion 
shape and size, as well as being involved in the viral budding 
process (Lamb and Krug 1996; Hui et al 2003). The virus is 
then released by budding from the cell surface membrane, 
which is facilitated by the NA.
Inﬂ  uenza ecology
Inﬂ  uenza A viruses infect a wide range of species such as 
birds, seals, horses, man and pigs (Murphy and Webster 
1996). In contrast, inﬂ  uenza B viruses are mainly found in 
man. The natural reservoir for inﬂ  uenza A viruses is birds, 
with waterfowl being the most important host and will, for 
the foreseeable future, continue to be a threat to human 
health (Webster et al 1992; Murphy and Webster 1996). The 
virus may spread from this reservoir to other species includ-
ing man (Figure 2). Normally, avian inﬂ  uenza is a mild or 
asymptomatic intestinal infection in birds and the virus may 
be secreted in high titers through the cloacae for a period up 
to 30 days (Hinshaw et al 1980). The practice in many parts 
of the world of keeping free-ranging poultry close to the 
family dwelling, allowing both exchange of avian inﬂ  uenza 
with wild birds as well as facilitating zoonoses, is considered 
to be unsafe (reviewed in Webster and Bean 1998).
The receptor binding speciﬁ  city of the surface glycopro-
tein HA is an important determinant of host range. Only one 
amino acid substitution in HA (226Leu→Gln) may change 
the receptor speciﬁ  city of HA (Eisen et al 1997), shifting from 
human (SAα-(2, 6)Gal) to avian (SAα-(2, 3)Gal) receptor 
preference. Humans also express a low level of the avian 
receptor (SAα-(2, 3)Gal) in the lower respiratory tract, which 
may explain why avian inﬂ  uenza virus only rarely infects 
man (Shinya et al 2006). In addition to the HA gene, the 
pathogenicity of inﬂ  uenza is also determined by a number of 
gene segments including the polymerase complex, the NS1 
and the NA (Goto and Kawaoka 1998; Basler et al 2001; 
Taubenberger et al 2005).
Figure 1 Schematic ﬁ  gure of inﬂ  uenza virus. On the surface of the virus there are three viral proteins, haemagglutinin (HA), neuraminidase (NA) and the matrix 2 protein 
(M2). Underlining the viral envelope is the matrix 1 protein (M1), the nucleoprotein (NP) encapsidates the genome segments with one complex of the polymerase attached 
(PB1, PB2 and PA). The non-structural protein 2 (NS2) is also contained in the virion in low numbers.International Journal of COPD 2007:2(3) 232
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Inﬂ  uenza epidemiology
The annual inﬂ  uenza outbreaks usually start during the winter 
months in temperate climates. In contrast, in the tropics and 
subtropics inﬂ  uenza virus may be isolated throughout the 
year. The number of suspected inﬂ  uenza cases, designated 
inﬂ  uenza like illness (ILI), is a frequently used as a mea-
sure of epidemic activity (Fleming et al 2000; Stephenson 
and Zambon 2002). However, there is more than one case 
deﬁ  nition of ILI used. The WHO deﬁ  nes ILI as a sudden 
onset of fever (>38 °C), cough or sore throat in the absence 
of other diagnoses (WHO 1999), whereas others have used 
a sudden onset of fever, cough and fatigue (Thursky et al 
2003), or fever as well as least two of the following symp-
toms: headache, cough, sore throat and myalgia (Boivin et al 
2000). Generally, inﬂ  uenza A H3N2 normally results in the 
most serious illness, B viruses intermediate and inﬂ  uenza A 
H1N1 cases present with the mildest manifestations (Monto 
et al 1985). Inﬂ  uenza A viruses are normally responsible 
for four-fold more hospitalizations than inﬂ  uenza B viruses 
(Murphy and Webster 1996).
Inﬂ  uenza related deaths are frequently under-reported 
because inﬂ  uenza often exacerbates underlying disease, 
which may be recorded as the primary cause of death 
(Nicholson 1998). The number of inﬂ  uenza related deaths 
is therefore often monitored as the number of excess deaths 
compared to a period without (known) inﬂ  uenza activity. 
Inﬂ  uenza mortality usually occurs in the “at risk” groups; 
people with underlying chronic medical conditions like 
COPD, diabetes, cancer and heart disease as well as in the 
elderly. Inﬂ  uenza related deaths worldwide are estimated to 
be about 1 million people each year (WHO 2002; Yewdell 
and Garcia-Sastre 2002) and in the USA about 60%–70% 
of deaths occur in people over 65 years old (Perrotta et al 
1985). However, the true number of inﬂ  uenza related deaths 
worldwide is difﬁ  cult to estimate, since most epidemiological 
data are derived from industrialized countries in the temper-
ate zone (WHO 2005).
Antigenic drift of inﬂ  uenza
Inﬂ  uenza is an RNA virus and as such has a high frequency of 
copy errors during replication due to a lack of proof-reading 
by the polymerase. This results in substitutions in the genome 
at a rate that is many-fold higher than that found for DNA 




























Figure 2 A simpliﬁ  ed overview of the ecology of inﬂ  uenza A virus. The subtypes that have been detected in each species are shown and the subtypes marked in bold are 
the highly pathogenic avian inﬂ  uenza subtypes that have caused illness in humans. The main reservoir of inﬂ  uenza A viruses is waterfowl, which may carry highly pathogenic 
subtypes of inﬂ  uenza without visible illness. The H5N1 has also been detected in domestic cats, however, little is known about their role in H5N1 epidemiology. Currently, 
we do not have enough knowledge about the importance of migratory birds in the spread of inﬂ  uenza virus (hence the question mark). Interested readers can consult the 
reviews by Webster et al 1992 or Murphy et al 1996 for further information.International Journal of COPD 2007:2(3) 233
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The accumulation of mutations, particularly in the HA, 
may lead to changes in the antigenic signature of the virus 
allowing the virus to escape herd immunity and cause new 
outbreaks, a process called antigenic drift (Murphy and 
Webster 1996). Inﬂ  uenza A viruses mutate more frequently 
than inﬂ  uenza B viruses and hence inﬂ  uenza B is more 
antigenically stable (Yamashita et al 1988). The slower 
evolution of inﬂ  uenza B viruses may be attributed to a 
longer co-evolution in man and host speciﬁ  c adaptations 
(Webster et al 1992). The risk of reassorting with avian 
subtypes makes inﬂ  uenza A virus a particularly dangerous 
infectious agent for man.
Antigenic shift of inﬂ  uenza
During the 20th century there were three pandemics, namely 
in 1918, 1957 and 1968 (WHO 2005). The term pandemic is 
only used when an antigenic shift occurs and the novel inﬂ  u-
enza A subtype infects humans causing global widespread 
outbreaks resulting in substantial morbidity and mortality. 
The 1918 pandemic had the highest mortality rates of the 
20th century pandemics, causing approximately 40 million 
deaths worldwide, with an unprecedented number of deaths 
in young adults (review in Reid et al 2001).
Antigenic shift may occur after reassortment of viral 
genome segments from two different inﬂ  uenza A subtypes. 
When two viruses co-infect the same cell and exchange seg-
ments, a novel reassorted virus with new combinations of 
HA and NA surface glycoproteins may be generated. When 
a virus with a novel HA (and NA) spreads efﬁ  ciently in man, 
the virus may cause a pandemic (Webster et al 1992). These 
novel inﬂ  uenza A viruses cross the species barrier from the 
large avian reservoir and can strike at unpredictable inter-
vals. Pigs, having receptors for both the human and avian 
inﬂ  uenza viruses, and are thought to play a role as a “mixing 
vessel” producing new reassortments of inﬂ  uenza A virus 
(see Figure 2). The pandemics of 1957 and 1968 were the 
result of a reassortment between avian and human inﬂ  uenza 
viruses, possibly in pigs (Webster et al 1992).
An antigenic shift can also occur after direct transfer of 
an avian virus into man. The H1N1 virus responsible for the 
1918 pandemic was not a reassortant, but was transmitted to 
man in toto from an avian source (Taubenberger et al 2005). 
The zoonotic cases of avian H5N1 in Hong Kong in 1997 
and the ongoing zoonosis of H5N1 demonstrate that avian 
viruses can directly infect man and do not necessarily require 
a “mixing vessel” (Subbarao et al 1998; Chotpitayasunondh 
et al 2005). In fact, the genetic reassortment between avian 
and human subtypes could well take place in man. However, 
to date there has not been an adaptation of this novel H5N1 
subtype to allow a sustained human-to-human spread.
Vaccines and immunity
The two main types of inﬂ  uenza vaccine are inactivated 
virus, which is by far the most commonly used, and live virus 
vaccines. Inactivated vaccines are normally administered 
parenterally. In contrast, live virus vaccines are administered 
intranasally with an attenuated virus to produce a limited 
upper respiratory tract infection without causing any overt 
clinical illness. However, live inﬂ  uenza vaccines are not 
licensed outside Russia and the USA. In the USA, live 
vaccines are so far only recommended for healthy subjects 
5–49 years old, thus excluding their use in COPD patients 
(Harper et al 2005).
Current inactivated inﬂ  uenza vaccines are trivalent con-
taining strains from two inﬂ  uenza A subtypes (H1N1 and 
H3N2) and one inﬂ  uenza B variant. The vaccine is normally 
administered during October and November in the northern 
hemisphere. A single-dose regime is mostly used, but for pre-
school children two doses are recommended at one-months 
intervals. The vaccine strains need to be epidemiologically 
relevant, and the WHO updates their strain recommenda-
tion on an annual basis for each hemisphere. The selected 
strains are either reassorted with a high-growth laboratory 
strain or adapted to give better yields in embryonated eggs. 
The reassorted strain expresses the desired HA and NA of 
the ﬁ  eld virus, while maintaing the high growth potential 
in eggs (Kilbourne 1969). Embryonated hens’ eggs are the 
most commonly used vaccine substrate. However, some 
vaccine manufacturers are now licensing their cell culture 
based vaccines. This will give the vaccine industry greater 
ﬂ  exibility and allow scaling up their production if a sudden 
surge in demand should occur.
Formulation of inactivated vaccines
There are three main formulations of inactivated vaccines 
(extensively reviewed in Furminger 1998). Whole virus 
vaccine is inactivated by chemical agents (eg, formaldehyde 
or β-propiolactone) in a procedure that does not destroy the 
viral envelope (Goldstein and Tauraso 1970). This type of 
vaccine was widely utilized until the end of the 1970s, but 
its use was largely discontinued due to a somewhat higher 
frequency of side reactions (Barry et al 1976; Boyer et al 
1977; Gross et al 1977; Hehme et al 2002, 2004). A split 
virus vaccine is produced using chemical agents (eg, ether or 
tributyl phosphate) to disrupt the viral envelope (Davenport 
et al 1960; Barry et al 1976). Immunization with split virus International Journal of COPD 2007:2(3) 234
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vaccine produces fewer side reactions (ie, has a lower reacto-
genicity), but has also a somewhat reduced immunogenicity 
compared to whole virus vaccine (Barry et al 1976; Gross 
et al 1977). A third vaccine formulation, the subunit type, 
consists of highly puriﬁ  ed surface antigens, HA and NA, 
and is the least reactogenic inﬂ  uenza vaccine on the mar-
ket today (Potter et al 1975). All inactivated vaccines are 
administered parenterally, either intramuscularly or deep 
subcutaneously. However, more recent studies using highly 
puriﬁ  ed virus have found that split and whole virus vaccine 
induce similar levels of side reactions (Hehme et al 2002; 
Hehme et al 2004).
The normal adult human dose is standardized to a concen-
tration of 15 μg HA per strain, and thus the trivalent vaccine 
contains a total of 45 μg of HA. Current inﬂ  uenza vaccines 
are not adjuvanted, the use of adjuvants may be necessary 
for pandemic vaccines based on avian inﬂ  uenza viruses 
where the vaccine recipient would be immunologically naïve 
(Stephenson et al 2004).
Immunity after vaccination
Humans have generally experienced a number of inﬂ  uenza 
infections, which prime the immune system and create an 
immunological memory (Smith 1977; Palladino et al 1995; 
Tamura and Kurata 2004). Upon vaccination with inactivated 
vaccine, reactivation of immunological memory results in 
production of mainly IgG as well as some IgA antibodies 
(Brokstad et al 1995; Brokstad et al 2002; Couch 2003; 
Guthrie et al 2004). In contrast, after a natural infection 
the immune response will elicit more IgA antibodies and 
a cellular T-cell response (Beyer et al 2002). If there is no 
pre-existing immunity (for example in children), two doses 
of vaccine are recommended given at least one month apart 
to achieve a satisfactory immune response (Harper et al 
2005). It is likely that a two dose regime will be required for 
a pandemic vaccine containing a novel inﬂ  uenza subtype, in 
addition to the use of an adjuvanted formulation (Stephenson 
et al 2003; Hehme et al 2004).
The systemic response after vaccination is rapid in 
healthy subjects with the antibody secreting cell response 
peaking after one week, while the serum antibody continues 
to increase up to 2–3 weeks after vaccination (Cox et al 1994). 
The concentration of inﬂ  uenza-speciﬁ  c serum antibody then 
wanes over time, but remains elevated at least 8 months post 
vaccination (Clark et al 1983). The importance of serum anti-
body is shown by the fact that the higher the serum antibody 
level, the less likely the person is to experience clinical illness 
upon subsequent infection (Hobson et al 1972; Kendal et al 
1982). Passively derived serum IgG probably leaks through 
the infected epithelial cell layer and neutralizes the virus and 
thus prevents binding to the cellular receptor (Tamura and 
Kurata 2004). IgG diffuses more readily across the alveolar 
wall in the lower respiratory tract than across the epithelial 
cells in the upper airways (Murphy 2005), which makes IgG 
antibodies particularly important in avoiding the most serious 
complications of infection.
COPD patients have a damaged epithelial cell layer and 
it has been shown in experimental models for asthma and 
chronic bronchitis, a lasting change in the airway epithelium 
and smooth muscle behavior after viral infection (Holtzman 
et al 2005). These authors have hypothesized a viral cause of 
both acute and chronic manifestations of asthma and chronic 
bronchitis. Studies in healthy individuals and animal models 
have shown apoptosis of cells in the epithelial cell layer and 
the resulting inﬂ  ammation also attract effector cells to the site 
of infection causing further cell death (Brydon et al 2005). 
This could have consequences also for the immune response 
in the damaged lungs of COPD sufferers, but no study to date 
has adequately addressed this issue. A thorough review of the 
aetiology of exacerbations in COPD sufferers has recently 
been published (Sapey and Stockley 2006).
Immunity after inﬂ  uenza infection
Initially, inﬂ  uenza virus replicates in the epithelial cells of 
the respiratory tract and this is also an important site for the 
immune response (Tamura and Kurata 2004). IgA is actively 
transported in its secretory form, S-IgA, across the epithelial 
surfaces of the respiratory tract and neutralizes virus by bind-
ing to its surface proteins. Once the infection is established, 
a cytotoxic response is induced, often against the internal 
viral proteins, and is involved in viral clearance and recovery 
from infection (Sambhara et al 2001; Takada et al 2003). The 
internal inﬂ  uenza proteins are more conserved than HA and 
NA, thus memory T-cells may be more cross-reactive against 
drifted viruses and possibly across inﬂ  uenza A subtypes.
Infection-induced immunity is thought to be long-lived, 
but will more or less become redundant due to the continuous 
antigenic changes of the virus. A special case was demon-
strated when the H1N1 virus re-appeared in 1977, which had 
circulated 20 years earlier (Dowdle 1999). Before the ﬁ  rst 
H1N1 wave, antibodies were only detected in people that were 
in their childhood in the 1950s and not in older or younger in-
dividuals (Haaheim 2003). The long-lived immune response to 
inﬂ  uenza virus experienced in early childhood is often referred 
to as ‘Antigenic Sin’ (Francis et al 1953). During the ﬁ  rst wave, 
people under the age of 20 were almost exclusively infected International Journal of COPD 2007:2(3) 235
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(Potter 1998) and they also had a marked lower immune re-
sponse to inactivated vaccines containing H1N1, suggesting 
that they did not have any immunological memory against 
this virus (Smith 1977). The 1977 virus was antigenically 
very similar to a 1950 isolate and was possibly inadvertently 
released into the human population (Palese 2004).
Target groups for vaccination
The WHO has issued a priority list of groups, which should be 
annually vaccinated (Listed in full in Table 2 (WHO 2005)). 
These groups are: (1) Residents of institutions for the elderly 
or the disabled; (2) Elderly non-institutionalized individuals 
with certain chronic medical conditions; (3) Other individuals 
in the community with certain chronic medical conditions; (4) 
Individuals who are above a nationally deﬁ  ned age limit; and 
(5) Other groups deﬁ  ned on the basis of national data such 
as those with frequent contact with high-risk persons, health 
care workers, pregnant women and children age 6–23 months 
old. The WHO has to date not issued any recommendations 
on the use of live inﬂ  uenza vaccines (WHO 2005).
Since inﬂ  uenza strains are prone to drift antigenically 
from one inﬂ  uenza season to the next, annual vaccination 
is recommended. Repeated inﬂ  uenza vaccination does not 
compromise the immune response, and should therefore not 
be used as an argument against annual vaccination (Keitel 
et al 1997; Beyer et al 1999).
Safety of inactivated inﬂ  uenza 
vaccines
More than 300 million doses of inﬂ  uenza vaccines are 
administered each year and the vaccine has an excellent 
safety record (Beyer et al 2002). Local side reactions usually 
occur in 15%–20% of the vaccinees, most commonly pain 
and redness at the injection site (WHO 2005). Transient and 
mild systemic reactions can also occur and include low-grade 
fever and headache, especially in children, but generally do 
not interfere with daily activities (Wiselka 1998).
Most people can be vaccinated without any complica-
tions. However, children younger than 6 months and people 
with known allergies to egg protein are advised against 
vaccination, whereas persons with an acute febrile illness 
should just postpone their vaccination until they have recov-
ered (Wiselka 1998; WHO 2005). However, a mild febrile 
illness is not considered a contraindication to vaccination 
(Harper et al 2005).
Inﬂ  uenza vaccination is recommended for a number 
of groups with underlying medical conditions and there is 
considerable information on the vaccine’s safety in these 
patients. A good safety record has been observed using in-
activated inﬂ  uenza vaccines in patients with COPD (Howells 
and Tyler 1961; Poole et al 2000; Wongsurakiat et al 2004) In 
adults with asthma there is a very low incidence of clinically 
signiﬁ  cant adverse reactions, for example, out of 40 million 
vaccine doses administered to such patients, only 5 cases of 
asthma exacerbations were reported over a ten-year period 
(Palache and van der Velden 1992). In asthmatic patients 
on oral steroid therapy, no serious local or systemic side 
reactions were reported after vaccination with an inactivated 
inﬂ  uenza vaccine (Park et al 1996).
Inﬂ  uenza vaccination will of course only protect against 
illness caused by inﬂ  uenza virus and not by other acute 
respiratory infections as shown in a recent study where 
the incidences of respiratory illnesses over a year was not 
affected by inﬂ  uenza vaccination (Wongsurakiat et al 2004). 
This is to be expected as, at least in the temperate zone, inﬂ  u-
enza normally is only epidemic for a few months each year. 
About 30% of exacerbations of COPD are caused by viral 
pathogens, and of these less than half are caused by inﬂ  uenza 
(Johnson and Stevenson 2002; Cameron et al 2006). Even so, 
inﬂ  uenza vaccination clearly reduced the frequency of exac-
erbations in COPD cohorts (Poole et al 2000). Some COPD 
patients occasionally report a worsening of their condition 
immediately following vaccination. However, in a recent 
study no increased usage of corticosteroids was found after 
vaccination (Tata et al 2003). People with asthma and COPD 
are considered to be one of the groups that beneﬁ  t most from 
inﬂ  uenza vaccination, consequently they are included in the 
“at risk” groups by the WHO (WHO 2000, 2005).
Vaccine efﬁ  cacy: measurement 
and contributing factors
The protection elicited by inﬂ  uenza vaccine is notoriously 
difﬁ  cult to quantify. The term vaccine efﬁ  cacy refers to 
Table 2 Target groups for vaccination (WHO 2005)
1  Residents of institutions for the elderly or the disabled; 
2  Elderly non-institutionalised individuals with 1 or more of the 
  following chronic conditions, chronic cardiovascular, pulmonary, 
  metabolic or renal disease, or who are immunocompromised; 
3  Other individuals (adults and children aged >6 months) in the 
  community who have chronic cardiovascular, pulmonary, metabolic
  or renal disease, or are immunocompromised; 
4  Individuals who are above a nationally deﬁ  ned age limit irrespective
  of their medical risk status (most countries deﬁ  ne the limit 
  of age >65 years); 
5  Other groups deﬁ  ned on the basis of national data such as those
  with frequent contact with high-risk persons, health care workers,
  pregnant women and children 6–23 months old. International Journal of COPD 2007:2(3) 236
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well-controlled experiments with a placebo control group 
(Hannoun et al 2004) and sometimes involves young 
study subjects with a better than average health. Vaccine 
effectiveness is used to describe the protective effect of the 
vaccine when used as a part of a public health scheme and 
can be considerably lower than the efﬁ  cacy. Both vaccine 
effectiveness and efﬁ  cacy are highly dependent upon the 
speciﬁ  c outcome being measured, the degree of antigenic 
match between epidemic virus in circulation and the vaccine 
strain, as well as the severity of the epidemic. However, the 
vaccine efﬁ  cacy, especially when measured by serological 
correlates of protection, may be an underestimate of the true 
effect of vaccination, partly because little data is available on 
the number of vaccinees who undergo a sub-clinical inﬂ  uenza 
infection (Palache 1997).
Vaccine efﬁ  cacy is commonly measured using surrogate 
correlates of protection. The serum antibody response is often 
tested by the haemagglutination inhibition (HI) assay (Hobson 
et al 1972; Kendal et al 1982). An HI titer 40 indicates a 50% 
protective level against inﬂ  uenza (Hobson et al 1972; Kendal 
et al 1982). The level of seroprotection, ie, the percentage of 
vaccinees that have an HI titer after vaccination of at least 40, 
was found in a meta-study of mainly young health subjects 
under 65, to be 80%–90% (Table 3) (Beyer et al 2002). Vac-
cination with inactivated inﬂ  uenza vaccine has been shown to 
prevent laboratory conﬁ  rmed inﬂ  uenza in 70%–90% of healthy 
adults (Ruben et al 1973; Wilde et al 1999; Bridges et al 2000; 
Beyer et al 2002; Kawai et al 2003; Harper et al 2005; WHO 
2005). The vaccine efﬁ  cacy is reduced if a more general clini-
cal outcome is measured, for instance one study showed only 
a 25% reduction in upper respiratory tract illness and a 43% 
reduction in absenteeism from work (Nichol et al 1995).
A signiﬁ  cant factor when evaluating the efﬁ  cacy of the 
vaccine is the antigenic match between the vaccine strains and 
the circulating inﬂ  uenza viruses in the community. Normally, 
the antigenic difference between them is trivial, but oc-
casionally there is a mismatch. Due to the poorer immune 
response in the elderly, this may be more important in this 
group than in healthy adults (de Jong et al 2000). In healthy 
subjects, however, the vaccine is effective (49%–53%) in 
preventing illness also in years with a sub-optimal match 
between the vaccine and circulating inﬂ  uenza strains (Pyhälä 
et al 2001; Ritzwoller et al 2005). The level of circulating 
inﬂ  uenza in the community also complicates the calculation 
of the effectiveness of the vaccine. In years of high inﬂ  uenza 
activity and widespread outbreaks, the vaccine will show a 
higher efﬁ  cacy (Jefferson et al 2005) and better cost/beneﬁ  t 
ratio (Nichol et al 2005; Turner et al 2005).
Efﬁ  cacy and effectiveness 
in “at risk” populations
The immune response elicited after inﬂ  uenza vaccination 
in the elderly is poorer than in younger subjects (Table 3) 
(Palache et al 1993), which is important for COPD patients 
as they are often at an advanced age (Vilkman et al 1996). 
This is reﬂ  ected in the inﬂ  uenza vaccine licensing criteria 
in the EU, which have less stringent requirements for the 
vaccine’s immunogenicity in subjects over 60 years of age 
(CHMP 1997). In older patients (>65), a lower number of 
subjects elicits an increase in serum antibody after vaccina-
tion than in healthy adults, and the seroprotection rate was 
generally 40%–70% (Gross et al 1987; McElhaney et al 
1993; Palache et al 1993; Govaert et al 1994; McElhaney 
et al 2005). Similar ﬁ  ndings were observed in a trial with 
COPD patients with 45%–87% achieving a protective HI titer 
(Wongsurakiat et al 2004). However, institutionalized elderly 
and inﬁ  rm subjects often have a particularly poor response 
after vaccination (Gross et al 1989). For ethical reasons few 
Table 3 The efﬁ  cacy of inﬂ  uenza vaccine in different population groups from representative studies
  Serum HI  Laboratory   Hospitalization  Death  References
   conﬁ  rmed   P&I   
     inﬂ  uenza       
Adults   83−90%   73−78%       Beyer 2002 
Elderly, no other risk  37−86%   30−81%   33%   50−75%   Goevert 1994, 
        Fleming  1995,  Vu  2002, 
        McElhaney  2005 
Elderly, institution     53%   50%   68%   Gross 1995 
and non-institution          
Elderly, chronic       52%   45−70%   Nichol 1999 
lung diseases          
COPD patients   45−87%       45%   Wang 2006, 
        Wongsurakiat,  2004International Journal of COPD 2007:2(3) 237
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case-control studies have been undertaken investigating the 
efﬁ  cacy of inactivated vaccines in the “at risk” groups.
A much used marker for measuring vaccine efﬁ  cacy is 
the prevention of ILI. Some ILI cases are not due to inﬂ  uenza 
virus, but other respiratory pathogens and the vaccine efﬁ  cacy 
in the elderly and probably also COPD sufferers against ILI is 
relatively low (35%) (Vu et al 2002). The positive predictive 
value of ILI actually being due to inﬂ  uenza is 23%–60%, and 
is very dependent on the case deﬁ  nition (Thursky et al 2003). 
The study conducted by Wongsurakiat et al showed a sig-
niﬁ  cant reduction (66%) in the number of ILI cases between 
vaccinated and unvaccinated COPD patients, despite a small 
patient group size (Wongsurakiat et al 2004). Using a more 
speciﬁ  c inﬂ  uenza diagnosis, namely laboratory conﬁ  rmed 
inﬂ  uenza, the vaccine had a 58% efﬁ  cacy in healthy elderly 
subjects (Govaert et al 1994). This is similar to the reduction 
of laboratory conﬁ  rmed inﬂ  uenza observed in adults 16–64 
years old (Kawai et al 2003).
During the inﬂ  uenza season there is an increase of hospi-
talization of COPD patients, clearly demonstrating the impact 
inﬂ  uenza illness can have on this group of patients (Yap et al 
2004). Inﬂ  uenza vaccination, however, only partly protects 
this group against hospitalization for pneumonia and inﬂ  uenza 
(P&I) as there are several causes not related to inﬂ  uenza for P&I. 
Several studies in the elderly population, found the reduction in 
hospitalization for P&I to be signiﬁ  cant after inﬂ  uenza vaccina-
tion (33%–52%) (Gross et al 1995; Nichol et al 1996; Vu et al 
2002). There is an rapid deterioration in the quality of life with 
increasing number of COPD exacerbations (Niewoehner 2006) 
and inﬂ  uenza vaccine has been shown to have a 75%–80% effec-
tiveness in reduction of acute respiratory illnesses, independently 
of the severity of COPD (mild, moderate and severe) (Howells 
and Tyler 1961; Wongsurakiat et al 2004).
Older people may not fully recover after an inﬂ  uenza 
infection and thus one signiﬁ  cant consequence of hospi-
talization may be permanent disability (McElhaney 2005). 
Inﬂ  uenza vaccination reduced the hospitalization rate by 52% 
in elderly patients with chronic lung disease (Nichol et al 
1999). An additional strategy for protecting these residents 
is therefore vaccination of the nursing-home staff caring for 
them (Potter et al 1997). Vaccination of family members 
and other close contacts will therefore indirectly protect the 
“at risk” groups (Piedra et al 2005) and is a policy that is 
advocated by the WHO (WHO 2005).
The efﬁ  cacy of inactivated inﬂ  uenza vaccines in pre-
venting inﬂ  uenza related deaths is 50%–75% in elderly “at 
risk” groups (Fleming et al 1995; Gross et al 1995; Nichol 
et al 1996; Jefferson et al 2005). This has been veriﬁ  ed by 
trials in non-institutionalized elderly (Vu et al 2002) and in 
elderly with pulmonary or heart diseases (Nichol 1999). A 
large recent study involving over 100,000 people in Taiwan 
investigating the impact of inﬂ  uenza vaccination on mortal-
ity, also demonstrated a 45% reduction in mortality of COPD 
patients following inﬂ  uenza vaccination and the vaccination 
was strongly correlated with prevention of death from lung 
disease in general (Wang et al 2007).
The assumption that inﬂ  uenza vaccination also appears 
to protect the vaccinee from all causes of death and not 
only inﬂ  uenza related deaths, is controversial (Simonsen 
et al 2005) and underlines the difﬁ  culty in determining the 
vaccines effectiveness in large cohort studies. The efﬁ  cacy 
of inﬂ  uenza vaccines to prevent serious inﬂ  uenza-related 
complications in the elderly, can be increased by using both 
inﬂ  uenza and pneumococcal vaccines and results in a reduc-
tion of the number of hospitalizations. Both vaccines are safe 
and can be co-administered without impairing the antibody 
response to either vaccine (CDC 1997).
Future challenges in the use 
of inﬂ  uenza vaccines
One of the most critical challenges is to increase the cover-
age rate of current inﬂ  uenza vaccines among the “at risk” 
groups, and many developed countries have adopted a policy 
to increase vaccine uptake. The World Health Assembly has 
set a goal of annual immunization of at least 75% of people 
over 65 years of age by 2010 (WHO 2005). In recent years, 
some countries have had vaccine supply problems, which 
can only be rectiﬁ  ed by increasing vaccine production and 
encouraging more manufacturers to produce inﬂ  uenza vac-
cine. This will beneﬁ  t not only COPD sufferers, but also the 
general public, as the industry’s production capacity will be 
better placed to meet the considerable demand for vaccine 
when a new pandemic strikes (Wood 2001). Most inﬂ  uenza 
vaccine manufacturers use embryonated hens’ eggs as the 
vaccine substrate. Quality-assured eggs cannot be delivered 
at short notice, as the manufacturers need to plan their pro-
duction a year in advance. The use of cell culture systems 
that are more easily scaled up provides more ﬂ  exibility to 
accommodate the increasing demand for inﬂ  uenza vaccines 
and improves pandemic preparedness.
Currently used inactivated inﬂ  uenza vaccines are safe, 
but the immunogenicity, especially in elderly, is suboptimal. 
There are a number of different approaches being employed 
to improve the vaccine efﬁ  cacy. One option is to return to 
the use of the more immunogenic whole virus vaccine for-
mulation, which in recent trials has also been shown to have International Journal of COPD 2007:2(3) 238
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an acceptable reactogenicity proﬁ  le (Hehme et al 2002) or 
alternatively, to use a virosomal inﬂ  uenza vaccine, which has 
the viral surface antigens in a reconstituted viral envelope 
(Huckriede et al 2005). The vaccine immunogenicity can 
also be increased by adjuvanting the vaccine. This raises new 
safety issues, especially in patients on medication. However, 
one of these adjuvants, MF59, has been shown not to cause 
more side reactions in COPD patients on steroid therapy than 
healthy subjects (de Roux et al 2005). Several trials have 
investigated the combined effect of both live and inactivated 
inﬂ  uenza vaccination, this is however, not considered as a 
practical routine procedure (Harper et al 2005). To date, no 
beneﬁ  cial effect of vaccination with both live and inactivated 
inﬂ  uenza vaccines has been found in older patients with 
COPD (Gorse et al 2003; Gorse et al 2004).
Conclusion
Inﬂ  uenza remains today an important cause of morbidity 
and mortality, especially in groups with underlying medi-
cal conditions like COPD. Inactivated inﬂ  uenza vaccines 
have been used for many years with hundreds of millions of 
doses administered and have an excellent safety record in 
all patients groups. There have been relatively few studies 
based solely on COPD patients, but nonetheless the conclu-
sion is that there is enough evidence to recommend annual 
vaccination in this group (Poole et al 2000; Baydur 2004; 
Wongsurakiat et al 2004). Even if the efﬁ  cacy of current 
inﬂ  uenza vaccine is not optimal, there is no doubt that its use 
in COPD sufferers will continue to reduce morbidity, save 
lives, and reduce health care costs.
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